David A. Eiznhamer

Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel drugs in therapeutic areas of infection, cancer and inflammation. Its product candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-aquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia. The company was founded by Michael T. Flavin on January 1, 1999 and is headquartered in Woodridge, IL.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Part of DGI Resolution, Inc., MediChem Life Sciences, Inc. provides research and drug discovery services. The company is based in Woodridge, IL. The company was founded in 1987 by Michael T. Flavin. MediChem Life Sciences was acquired by deCODE genetics, Inc. on March 18, 2002 for $52.85 million.